Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 7, 2014

Primary Completion Date

October 23, 2020

Study Completion Date

October 23, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

POM

DRUG

Steroids

DRUG

PLD

DRUG

CFZ

DRUG

BTZ

DRUG

CLA

DRUG

CY

Trial Locations (12)

37660

Wellmont Medical Associates Oncology and Hematology, Kingsport

44718

Gabrail Cancer Center, Canton

57701

Rapid City Regional Hospital, Rapid City

87401

San Juan Oncology Associates, Farmington

89502

VA Sierra Nevada, Reno

90069

James R. Berenson, MD, Inc., West Hollywood

91307

Wellness Oncology and Hematology, West Hills

92024

California Cancer Associates for Research & Excellence (cCARE), Encinitas

92262

Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs

92404

Inland Hematology Oncology Medical Group, Inc, San Bernardino

92708

Compassionate Care Research Group, Fountain Valley

98502

Vista Oncology, Olympia

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Oncotherapeutics

INDUSTRY